Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2860044 | 0.92 | KDM4E (0.68) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL31126834 | 0.92 | KDM4E (0.68) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL27465197 | 0.88 | MEN1 (0.59) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL11370286 | 0.88 | MEN1 (0.59) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL10489819 | 0.85 | KMT2A (0.63) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL19805148 | 0.85 | MEN1 (0.68) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL5442803 | 0.84 | KMT2A (0.71) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL11091761 | 0.84 | CYP1A2 (0.55) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL10874779 | 0.84 | NPC1 (0.68) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL28401182 | 0.84 | ALDH1A1 (0.72) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632834-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOUYSSOU THIERRY | 2008-08-14 | — | — | US | disclosed |
| US-7375104-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20070066609-A1 | Long acting beta-2-agonists and their use as medicaments | BOUYSSOU THIERRY | 2007-03-22 | — | — | US | disclosed |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | US | disclosed |
| US-7160882-B2 | Long acting β-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-09 | — | — | US | disclosed |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| CN-1653042-A | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-10 | — | — | CN | disclosed |
| US-5654306-A | ALZHEIMER'S DISEASE; COGNITION ACTIVATORS; BRAIN AND PSYCHOLOGICAL DISORDERS | EISAI CO., LTD. (JP) | 1997-08-05 | — | — | US | disclosed |
| US-5424318-A | Piperidine derivative and pharmaceutical composition | EISAI CO., LTD. (JP) | 1995-06-13 | — | — | US | disclosed |
| US-5306720-A | Treatment of cerebrovascular disorders | EISAI CO., LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0229391-B1 | PIPERIDINE DERIVATE, ITS USE AND PHARMACEUTICAL COMPOSITION CONTAINING IT | Eisai Co., Ltd. (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-5118684-A | For cardiovascular disorder | EISAI CO., LTD. (JP) | 1992-06-02 | — | — | US | disclosed |
| US-5039681-A | Cognition activators, brain disorders, psychology | EISAI CO., LTD. (JP) | 1991-08-13 | — | — | US | disclosed |
| US-4942169-A | COGNITION ACTIVATORS, ANTICHOLINESTERASE | EISAI CO., LTD. (JP) | 1990-07-17 | — | — | US | disclosed |
| US-4849431-A | ANTICHOLINESTERASE ACTIVITY | EISAI CO., LTD. (JP) | 1989-07-18 | — | — | US | disclosed |
| EP-0229391-A1 | Piperidine derivate, its use and pharmaceutical composition containing it | Eisai Co., Ltd. (JP) | 1987-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066609-A1 | Long acting beta-2-agonists and their use as medicaments | ADRB2, ADRB1, CHRM1 | CYP1A2 349/4885SMN1; SMN2 1859/4885CYP2C19 1380/4885 |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | ADRB2, ADRA2A, ADRB1 | CYP1A2 185/4885SMN1; SMN2 2334/4885CYP2C19 1381/4885 |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | ADRB2, ADRA2A, ADRB1 | CYP1A2 769/4885SMN1; SMN2 1213/4885CYP2C19 3479/4885 |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | ADRB2, ADRB1, CHRM1 | CYP1A2 346/4885SMN1; SMN2 1839/4885CYP2C19 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.